Discover your potential savings with our ROI Calculator
Self-guided Product Tours
Product Demo Videos
Pricing
Recent Blogs
Recent Infographics
Recent Case Studies
Featured Case Study
ComplianceQuest Medical Devices QMS Success Stories eBook
Recent Checklists
Featured Checklist
Complaint Handling Process for MedTech and Life Science Companies
Course Offerings
Recent CQ Guides
Datasheets
Brochures
Demo Center
Videos
Podcasts
Recent Webinars
Webinar
Unlocking the Value of Complaints
Recent Whitepapers
Whitepaper
Why You Need to Digitally Transform Your QMS
Compliance
Toolkits
Infographic
Safety Technology Trends to Watch in 2023 (Infographic)
Recent Toolkits
Events and Webinars
Events
Upcoming Webinars
Featured Event
42nd SQA Annual Meeting
13 Apr, 2026
National Harbor, MD
About
About ComplianceQuest
Transform to a fully connected business with a next-generation AI-powered Product Lifecycle, Quality, Safety, and Supplier management platform, built on Salesforce.
Our connected suite of solutions helps businesses of all sizes increase quality, safety and efficiency as they bring their products from concept to customer success.
Meet the Leadership Team
Careers
Where Your Career Takes Flight: Join our dynamic team and be part of an innovative, collaborative and rewarding workplace culture.
Corporate Citizenship
Impact Through Action: How the ComplianceQuest team supports social causes and community engagement
Customers & Testimonials
Newsroom
The Pulse of ComplianceQuest: Our newsroom shares stories of innovation, progress, and change
Partners
Stronger Together: How our partnerships drive success and innovation
Upcoming Events
Much data and analysis surrounds cannabis and its usefulness in treating a whole range of diseases. The US Food and Drug Administration (FDA) has only approved one prescription drug product containing cannabidiol (CBD) – an ingredient in cannabis – to treat two rare, severe forms of epilepsy.
As of June 2019, 33 states allow the use of cannabis for medical purposes. At the federal level, though, cannabis has been classified as a Schedule I substance under the Controlled Substances Act. Schedule I substances are those with a high potential for dependency and no accepted medical use. Therefore, the distribution of marijuana is still a federal offense.
For the cannabis industry, constantly evolving regulations intertwined with a ripe opportunity, plays out interestingly.
A product recall, especially in healthcare and pertaining to medical marijuana, can damage the reputation of the company and affect sales. Therefore, it is essential to ensure compliance and quality at all times.
ComplianceQuest can help in the following ways, especially in the Cannabis sector:
A cloud-based EQMS like ComplianceQuest offers 12 key solutions ideal for the cannabis industry. It is built with automation and customization as its fundamental principles, thereby empowering the quality leader to choose the modules applicable to his/her context and scale as the enterprise evolves.
The EQMS solution drives efficiency and productivity while reducing the complexity of operations.
Currently, ComplianceQuest serves customers in over 1,000 locations across the world in several sectors including Healthcare and Life Sciences, Aerospace and Defense, Automotive, Cannabis, Consumer Packaged Goods, General Manufacturing and Hi-Tech.
Request a demo and we can explain how ComplianceQuest has delivered digital transformation and automation for healthcare, biotech and Cannabis firms around the world. Please email us at marketing@compliancequest.com to schedule a demo.
Learn about all features of our Product, Quality, Safety, and Supplier suites. Please fill the form below to access our comprehensive Demo Video.
Please confirm your details
By submitting this form you agree that we can store and process your personal data as per our Privacy Statement. We will never sell your personal information to any third party.
Enter Captcha
A product is a sum total of the inputs or the raw materials and the…
An Article on Sustained Compliance in the Cannabis Industry In July 2019, Health Canada issued…
The Cannabis Opportunity 2018 was an inflection point for the legal cannabis industry. In fact,…